Navigation Links
M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms
Date:3/1/2010

ORLANDO, FL - Researchers from The University of Texas M. D. Anderson Cancer Center have developed a new assessment tool to measure the severity of symptoms that can complicate stem cell transplantation. The tool assesses symptoms resulting from chronic graft-versus-host disease (cGVHD), and was presented with supporting research at the 2010 Bone and Marrow Transplant Tandem Meeting.

cGVHD - a chronic disease that requires the close management of symptoms for an indefinite period of time - usually develops more than three months after allogeneic hematopoietic stem cell transplantation (alloHSCT). cGVHD occurs when transplanted donor cells recognize the recipient as foreign and begin to attack the patient's organs and tissue.

The disease causes physically debilitating symptoms in 40 to 80 percent of transplant patients. Inadequate diagnosis and assessment is a major barrier to successful treatment of symptoms. According to the Center for International Blood and Marrow Transplant Research, approximately 19,000 allogeneic stem cell transplants were performed worldwide in 2006.

Using the existing M. D. Anderson Symptom Inventory, or core MDASI, a systematic, patient-reported outcome measure for clinical and research use, researchers developed a reliable and sensitive measuring system for cGVHD. On a scale of zero to 10, the new tool rates the severity of symptoms common to patients with the disease and to what extent those symptoms interfere with their daily life. The MDASI-cGVHD is one of 11 MDASI tools for symptom management used by clinicians at M. D. Anderson.

"There was a real need to develop this tool because chronic graft-versus-host disease is a vexing side effect that can become a serious condition in a very short period of time, threatening the success of the transplant and creating a dilemma for many patients who do not live near where they received their transplant or do not have access to a transplant specialist," said Loretta Williams, Ph.D., R.N., A.O.C.N., O.C.N., an instructor in the Department of Symptom Research at M. D. Anderson and lead author on the study. "Now we can assess quickly in person or over the phone whether a patient has developed symptoms of cGVHD and make arrangements for the patient to receive further assessment and treatment if necessary."

To develop the tool and establish its validity and reliability, researchers studied 116 patients with cGVHD and 58 without cGVHD, all of whom had had a transplant more than three months before. Using the core MDASI, each patient rated the severity of 13 symptoms common in cancer patients and to what extent those symptoms affected six "interference items," or general aspects and activities of daily life. Patients also rated 14 additional cGVHD-specific symptom items, generated from patient interviews and expert panel ratings.

Statistical analysis determined that five of the 14 cGVHD-related symptoms were clinically significant and unique to cGVHD patients, including muscle weakness, skin problems, eye problems, joint stiffness or soreness and changes in sexual function. The resulting comprehensive MDASI, which combined the 13 core symptoms with the five cGVHD symptoms, was sensitive to the presence of the disease. Results from the survey also correlated significantly with a patient's report of overall quality of life.

"For the first time ever, we have a reliable tool to provide better support to patients following their transplant," Williams said. "The survey will help open the conversation about chronic graft-versus-host disease between doctors and patients and identify complications more quickly. This may lead to better outcomes following stem cell transplantation."

The MDASI measures symptom severity and interference levels on a scale of 0 to 10, with zero meaning the symptom was not present and did not interfere with a patient's daily life, and 10 meaning the symptom's severity and interference in daily life was the worst imaginable. Core symptoms include pain, fatigue, nausea, shortness of breath, poor memory, difficulty sleeping, lack of appetite, dry mouth, sadness, vomiting and numbness or tingling. The six "interference items" include general activity, mood, work, personal relations, walking and overall enjoyment of life.


'/>"/>

Contact: Lindsay Anderson
lindsay.anderson@gabbe.com
212-220-4444
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. M.D. Anderson-led team reports possible key to autoimmune disease
2. UCI Medical Affiliates Inc. Opens a New Doctors Care Center in Anderson
3. M. D. Anderson-Prevention poll finds women can do more to prevent cancer...but arent
4. M. D. Anderson-Prevention poll finds women can do more to prevent cancer ... but arent
5. M. D. Anderson researchers identify tumor-suppressor gene for lung cancer
6. SEIU Endorses Anderson, Perea, and Perea in Fresno
7. M. D. Anderson research links diet, gardening and lung cancer risk
8. CyberKnife Centers of Miami, Palm Beach and Tampa Invited to Join M.D. Anderson Cancer Center Study
9. Naviscan PET Systems to Place High-Resolution PET Scanner at M. D. Anderson Cancer Center
10. M. D. Anderson nurses find empowerment in PACTs
11. M. D. Anderson nurse addresses lymphedema in breast cancer patients and survivors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology: